Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 Function

Abstract excerpt

Cytotoxic agents form the basis of most cancer therapies. These agents primarily affect rapidly proliferating cells, so their use incurs morbidity associated with damage to tissues such as bone marrow and gastrointestinal mucosa. Clinical outcome would be improved if it were possible to develop therapeutics with more specific activity against p53-deficient cancers, which account for over 50% of all cases. p53...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related Molecular Pathways
• Share to Microtubule and mitosis dynamics
• Share to Ubiquitin and proteasome pathways